Skip to main content
MedPathMedPath Home
Clinical Trials/CTRI/2022/07/043760
CTRI/2022/07/043760
Recruiting
Phase 4

The comparative efficacy of Buprenorphine-naloxone with moxonidine versus Buprenorphine-naloxone with clonidine for short term detoxification in opioid use disorders

Govt Medical College Rajindra Hospital Patiala0 sites0 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsHealth Condition 1: F112- Opioid dependence

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Health Condition 1: F112- Opioid dependence
Sponsor
Govt Medical College Rajindra Hospital Patiala
Status
Recruiting
Last Updated
3 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
3 years ago
Study Type
Interventional

Investigators

Sponsor
Govt Medical College Rajindra Hospital Patiala

Eligibility Criteria

Inclusion Criteria

  • •1\.Patient should fulfill the criteria of opioid use disorder as DSM\-5\.
  • •2\.Patient should be in withdrawal state at the time of admission (should fulfill the DSM\-5 criteria of opioid withdrawal syndrome).
  • •3\.Should be in the age group of 18 to 50 yrs.
  • •4\.Patients who will give voluntary informed consent for detoxification.

Exclusion Criteria

  • •1\.The patients who are diagnosed with any major physical illness, organic brain disease, epilepsy, schizophrenia, other psychosis or mental retardation will be excluded.
  • •2\.Current alcohol abusers or those taking any other drugs along with opioids will also be excluded.
  • •3\.Patients whose BP \< 90/60 mmHg will also be excluded for the risk of severe hypotension.
  • •4\.Patients with bradycardia (heart rate \< 50 beats/minute), severe bradyarrhythmia, malignant arrhythmia, heart failure or severe renal impairmentare excluded.
  • •5\.Pregnant and breast feeding women are to be excluded.
  • •6\.Elderly of age \> 60 yrs are excluded.
  • •7\.Patients on Beta blockers, Calcium channel blockers, Tricyclic antidepressants, Digitalis that interact adversely with Clonidine.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Not yet recruiting
Phase 3
Comparing how two different doses of an additive to bupivacaine heavy modifies the duration of action when used in lower limb surgeriesHealth Condition 1: S899- Unspecified injury of lower leg
CTRI/2022/01/039545Dr Ashik Sreekumar
Not yet recruiting
Phase 4
Adding additive to spinal drug to see for pain relief after surgeryHealth Condition 1: O- Medical and Surgical
CTRI/2024/03/063780Ananya Krishna T
Not yet recruiting
Phase 2
To Compare Two different Doses Of Drug Buprenorphine By Giving Block (Regional Anesthesia) and see for its Analgesic action and pain relief post operative periodHealth Condition 1: W19- Unspecified fall
CTRI/2020/06/026126Dr Dnyaneshwari Munde
Not yet recruiting
Phase 2
COMPARISON OF NALBUPHINE AND BUPRENORPHINE ADDED TO 0.5%LEVOBUPIVACAINE TO PRODUCE NERVEBLOCK FOR HAND SURGERIESHealth Condition 1: M808- Other osteoporosis with current pathological fractureHealth Condition 2: M628- Other specified disorders of muscle
CTRI/2021/09/036728sapthagiri institute of medical sciences and research center
Completed
Early Phase 1
Comparison of naloxone & buprenorphine on reversal of Opioid Overdose Syndrome and withdrawal in Methadone – Dependant Patients; An experimental StudyMethadone Overdose.Poisoning by Methadone
IRCT2015011020624N1Shahid Beheshti University of Medical Sciences90